Clinical trials: Streptococcus Pneumoniae Infections
Pneumonia
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
The group aged 18-59 years old, the group ≥60 years old, and the group aged 2-17 years old were successively assigned to the group.
- Trial name
- NCT05815264
- Testing
- 23-valent pneumococcal polysaccharide vaccine, pneumococcal vaccine polyvalent
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Pneumococcal Infection
9-valent CRM 197 Pneumococcal
The purpose of this study is to evaluate the safety and immune response of a conjugated pneumococcal vaccine compared to a licensed 23-valent polysaccharide pneumococcal vaccine in elderly adults.
- Trial name
- NCT00133549
- Testing
- PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer
HIV-1-infection, Human Immunodeficiency Virus
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Trial name
- NCT03729778
- Testing
- Prevnar-13
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Eastern Colorado Health Care System
Safety, Immunogenicity, Vaccine
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide…
- Conditions
- Safety, Immunogenicity, Vaccine, COVID-19 Vaccines, Influenza Vaccines
- Trial name
- QIV;PPV23 (NCT05298800)
- Testing
- Vaccine
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
COVID-19, Viral Pneumonia
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19.
- Conditions
- COVID-19, Viral Pneumonia, Pneumonia Due to Streptococcus Pneumoniae, Bacterial Pneumonia
- Trial name
- PROVID-CAPNETZ (NCT04952337)
- Where
- 15 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Hannover Medical School
Pneumococcal Infection
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when measured 1 month after the infant series, and to…
- Trial name
- NCT01692886
- Testing
- 7-valent Pneumococcal Conjugate Vaccine, 13-valent Pnumococcal Conjugate vaccine
- Where
- 4 sites in China
- Volunteers
- 1,674 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lower Respiratory Tract Infections
Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)
We are interested in developing new and better ways of diagnosing the cause of lower respiratory tract infections including pneumonia.
- Trial name
- NCT01861184
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3…
- Trial name
- NCT03384589
- Testing
- PCV13
- Where
- Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Infections, Streptococcal
Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose
This primary purpose of this study is the evaluation of the immunological persistence following completion of the 3-dose primary vaccination course with either a clinical or a commercial lot of pneumococcal conjugate vaccine…
- Trial name
- NCT01119625
- Testing
- Pneumococcal vaccine GSK1024850A, Infanrix-IPV/Hib
- Where
- 3 sites in Singapore
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease Prevention
Racial Disparities in Pneumococcal Vaccination in Managed Care
The goal of the study was to determine effectiveness of a telephone reminder to increase pneumococcal vaccination in a managed care population.
- Trial name
- NCT00229762
- Testing
- phone call from nurses - informational only
- Where
- United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Meningitis
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis
Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins.
- Trial name
- AddaMAP (NCT03480191)
- Testing
- Daptomycin
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pneumonia
A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia
Pneumonia, or lung infection, is usually treated with antibiotics targeted against the organisms that the physician guesses are causing the problem. The determination of the exact cause of a patient's pneumonia is difficult.
- Trial name
- NCT00867841
- Testing
- nasopharyngeal swab
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Hospital of Eastern Ontario
Pneumococcal Infections
Pneumococcal Vaccination of Fiji Infants
Pneumonia is the most common reason for admission of Fijian children to hospitals. The most common germ causing pneumonia is "streptococcus pneumoniae." It is a common cause of meningitis (infection around the brain and spinal…
- Trial name
- NCT00170612
- Testing
- Pneumovax 23, Prevnar
- Where
- Fiji
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Streptococcus Pneumoniae Infection, Respiratory Syncytial Virus Infections
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
This household-based prospective cohort study aims to stablish the household transmission of Respiratory syncytial virus and S. pneumoniae especially in the elderly and infants/children as well as inter-relationship between S.
- Trial name
- NCT05017519
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Pneumococcal Infections
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
This study is being conducted to evaluate the safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine (V114) compared to Prevnar™ in healthy adults and toddlers.
- Trial name
- NCT01215175
- Testing
- Prevnar™, V114, Aluminum Adjuvanted, V114, Aluminum Nonadjuvanted
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children
This study will aim to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' 10-valent pneumococcal conjugate vaccine GSK1024850A when co-administered with Japanese DTPa vaccine as a 3-dose…
- Trial name
- NCT01027845
- Testing
- Pneumococcal vaccine GSK1024850A, DTPa
- Where
- 16 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcal Infections
A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
Three dose primary vaccination with 11-valent pneumococcal conjugate vaccine administered concomitantly with Infanrix™ hexa to healthy infants between 8 to 16 weeks of age at the time of first vaccination.
- Trial name
- NCT00169481
- Testing
- Pneumococcal (vaccine)
- Where
- 56 sites in Germany
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline